Table 4 Patient stratification by antifibrotic medications
From: Association between weight loss and mortality in idiopathic pulmonary fibrosis
Characteristic | Nintedanib (n = 19) | PFD (n = 17) | P-value |
|---|---|---|---|
Age (years) | 71.3 ± 10.8 | 71.0 ± 6.5 | 0.93 |
Female Gender | 6 (31%) | 5 (29%) | 0.99 |
Weight at diagnosis (kg) | 87.63 ± 17.2 | 89.76 ± 15.4 | 0.70 |
BMI at diagnosis | 30.01 ± 5.2 | 29.9 ± 4.72 | 0.94 |
Smoking (any) | 15 (78%) | 12 (49%) | 0.70 |
FVC at diagnosis (L) | 2.87 ± 0.83 | 2.79 ± 0.75 | 0.75 |
FVC% Predicted | 80.0 ± 17.2 | 89.75 ± 15.4 | 0.70 |
DLCO at diagnosis (mL/min/mm Hg) | 9.61 ± 3.77 | 11.78 ± 4.30 | 0.12 |
Reflux disease | 7 (36%) | 7 (41%) | 0.99 |
Diabetes | 4 | 3 | 0.99 |
OSA | 1 | 2 | 0.59 |
Oxygen use | 6 | 6 | 0.99 |